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Fluorescence microscopyEnfuvirtide and T-1249 are two potent HIV-1 fusion inhibitor peptides. Recent studies indicate that lipids play an
important role in the mode of action of those bioactive molecules. Using a combined tandem atomic force mi-
croscopy (AFM)–epiﬂuorescence microscopy approach, we studied the interaction of both enfuvirtide and
T-1249 with supported lipid bilayers. Fluid (ld)-gel (so) and ld-liquid ordered (lo) phase-separated membrane
systems were tested. Results, especially for T-1249, show signiﬁcant lipid membrane activity at a 15 μMpeptide
concentration. T-1249, in opposition to enfuvirtide, induces an increase in membrane surface roughness, de-
crease in membrane ﬂuidity, bilayer thinning at ld domains and disruption of the so domain borders. In terms
of structural properties, both enfuvirtide and T-1249 possess distinct functional hydrophobic and amphipathic
domains of HIV gp41. While enfuvirtide only yields the tryptophan-rich domain (TRD), T-1249 possesses both
TRD and pocket-binding domain (PBD). TRD increases the hydrophobicity of the peptide while PBD enhances
the amphipathic characteristics. As such, the enhancedmembrane activity of T-1249may be explained by a syn-
ergism between its amphipathic N-terminal segment and its hydrophophic C-terminal. Our ﬁndings provide
valuable insights on themolecular-level mode of action of HIV-1 fusion inhibitors, unraveling the correlation be-
tween their structural properties and membrane interactions as a factor inﬂuencing their antiviral activity. Ulti-
mately, this work validates the applicability of a combined AFM and ﬂuorescence approach to evaluate the
mechanic and structural properties of supported lipid bilayers upon interactionwithmembrane-active peptides.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Fusion inhibitor (FI) peptides are a recent and promising class of
human immunodeﬁciency virus type 1 (HIV-1) antiretrovirals [1–3].
These molecules have demonstrated superior activity, which ultimately
led to the FDA-approval of enfuvirtide (T-20, Fuzeon) in 2003 [4]. FIs
present advantages in comparison to conventional anti-HIV drugs, such
as lower toxicity, increased biodistribution and reduced resistance levels.
FIs interfere with processes on the surface of cells and viruses before tar-
get cell infection. They inhibit highly conserved regions on the HIV-1 en-
velope glycoprotein 41 (gp41), the protein responsible for the viral pore
formation and membrane fusion [1,2]. More speciﬁcally, FIs interfere
with the formation of the 6-helix bundle (6HB) originated by the interac-
tion of the C-terminal heptad repeats (CHR or HR2) with the N-terminal
heptad repeats (NHR or HR1) of gp41 [5]. Enfuvirtide and other similar
peptide inhibitors are derived from CHR regions and, therefore, areecular, Faculdade de Medicina,
8 Lisbon, Portugal. Tel.: +351
anho).
rights reserved.able to competitively bind to the HIV-1 gp41 NHR. Although FIs typically
act via binding to gp41, some speciﬁcities related to their mode of action
should be pointed out [6–9]. On the native HIV-1 envelope structure the
conserved gp41 HR domains are most of the time shielded within the
gp120–gp41 envelope protein complex tridimensional structure and,
thus, hardly accessible in aqueous solution. The exception is during the
fusion process, when the HR domains are exposed in order to form the
6HB. Therefore, the inhibition by FIs must occur in a limited time win-
dow under extreme conﬁnement between the viral envelope and cell
plasmamembrane. Oneway to overcome these limitations is to improve
the interaction of FIs with lipid membranes. The viral and plasma cell
membranes can serve as platforms to concentrate the inhibitor mole-
cules that become this way directly accessible near the fusion site. A cor-
relation between membrane binding and antiviral efﬁcacy has been
established: for instance, FIs in which lipophilic moieties were added to
enhance the interaction with membranes have proven to possess im-
proved antiviral activity [10,11].
Enfuvirtide [12] has 36 amino acid residues, roughly including 26
residues of gp41 CHR and 10 residues from the gp41 membrane proxi-
mal external region (MPER). Part of the MPER is enriched in tryptophan
residues, forming a hydrophobic tryptophan-rich domain (TRD) (Fig. 1).
FP NHR CHR TM CT
Enfuvirtide
T-1249
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Trp-rich domain (TRD)Pocket-binding domain (PBD)
Fig. 1. Peptide fusion inhibitors and respectiveHIV-1 gp41 domains. Schematic representation of the location of theN- andC-terminal heptad repeats domains (NHR and CHR, respectively) on
gp41 and the sequences from the CHR–MPER region (residues 628–673, HxB2 strain), enfuvirtide (residues 638–673) and T-1249 (with elements fromHIV-1, HIV-2 and SIV). The underlined
andbold sequence represents the pocket-binding domain (PBD),whereas the underlined and italic sequence represents the Trp-rich domain (TRD). FP— fusion peptide; TM— transmembrane
domain; CT— cytoplasmic tail.
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and is involved in thebinding of themolecule to lipids [13]. Thus, this re-
gion is additionally known as lipid binding domain (LBD).
In comparison with other FIs, such as T-1249, which is a 39 amino
acid residue peptide derived from HIV-1, HIV-2 and simian immunode-
ﬁciency virus (SIV) [14], enfuvirtide possesses the TRD but lacks another
gp41 functional domain known as pocket bindingdomain (PBD) (Fig. 1).
This domain is responsible for the efﬁcient binding of FIs to the deep
pockets formed by gp41 NHR trimers [15]. Inhibitors that possess such
domains have demonstrated to inhibit the 6HB formation more efﬁ-
ciently [16].While the TRD seems to be the region responsible for the in-
teraction of FI peptides with lipid membranes, one cannot discard the
importance of the PBD in the interactions with lipids. For instance, we
previously showed that sifuvirtide, a recently developed peptide inhibi-
tor that lacks the TRD, is able to interact selectively with rigid phospha-
tidylcholine (PC) membranes [17,18], despite showing no signiﬁcant
afﬁnity for zwitterionic ﬂuid membranes. The involvement of the PBD
and TRD in membrane interactions may be expected from the theoreti-
calα-helical representation of the peptides. As seen in Fig. S1 (Appendix
A), if we depict enfuvirtide and T-1249 as α-helices, both peptides dis-
play a highly hydrophobic C-terminal helix (due to the presence of the
TRD), and T-1249 displays an N-terminal amphipathic helix (due the
presence of the PBD).
As such, the aim of this work was to unravel the molecular foun-
dation of FI peptides–lipid interactions using a combination of mi-
croscopy techniques. Microscopy allows obtaining high-resolution
information related to the interaction of enfuvirtide and T-1249
with lipid bilayers. It would enable, for instance, the imaging of the ef-
fects that those drugs have on the lipid bilayer architecture.
Atomic force microscopy (AFM), a scanning-probe technique able to
provide topography and force measurements [19], was coupled with
epiﬂuorescence microscopy [20] in order to obtain simultaneous topo-
graphic and bidimensional organization information on the lipid bilayer
properties. Supported lipid bilayers (SLB) deposited on freshly-cleaved
mica were used as our major lipid membranemodel. Despite the variety
of phospholipids that compose theHIV viral and cell plasmamembranes,
including phosphatidylcholines (PC), sphingomyelins (SM), phosphati-
dylethanolamines (PE) or phosphatidylserines (PS), in order to control
the ﬂuidity and phase properties of the bilayers and avoid biases arising
from the repulsion between anionic lipids and the negatively-charged
mica surface, mixtures containing solely uncharged PC and also choles-
terol were used throughout this work. Here we wanted to evaluate if
the presence of both PBD and TRD on a FI is in fact able to promote en-
hanced membrane interaction proﬁles that can be correlated with anenhanced antiviral activity. In the end, our results provide novel informa-
tion on the structural properties adopted by FIs while interacting with
membranes displaying speciﬁc phase separations.
2. Material and methods
2.1. Reagents and instruments
Enfuvirtide and T-1249 were kind gifts from Roche (Palo Alto, CA).
1-Palmitoyl-2-oleyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleyl-
sn-glycro-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC) were from Avanti Polar Lipids (Alabaster, AL), whereas choles-
terol (Chol) was obtained from Sigma (St. Louis, MO). 4-[2-[6-
(dioctylamino)-2-naphthalenyl]ethenyl]-1-(3-sulfopropyl)-pyridinum
(di-8-ANEPPS) was purchased from Molecular Probes, Invitrogen
(Carlsbad, CA).
Combined (and/or separated) AFM-epiﬂuorescence measurements
were performed on a JPK Instruments Nanowizard II (Berlin, Germany)
mounted on a Carl Zeiss Axiovert 200 inverted microscope (Jena,
Germany).
Solutions were prepared in 10 mM HEPES buffer pH 7.4, 150 mM
NaCl. This buffer was used throughout the studies, unless otherwise
stated. All the experiments were performed at 23 °C.
2.2. Planar supported lipid bilayer preparation
Supported lipid bilayers (SLB) were prepared by deposition of small
unilamellar vesicles (SUV), as described elsewhere [21,22]. Brieﬂy,
50 μL of 1 mM SUV suspension, obtained by sonication, was deposited
in the presence of 2 μL CaCl2 0.1 M on a freshly cleaved mica substrate
previously glued to a glass coverslip. The sample was then incubated
for amaximum time of 20 min at a temperature above the lipidmixture
phase transition temperature (Tm). After incubation, the sample was
rinsed at least 4 times with EDTA 1 mM and afterwards at least 10
timeswith buffer, in order to remove unfused vesicles. The planar bilay-
ers were then allowed to cool down and equilibrate for at least 1 h. On
the lipid membranes labeled with di-8-ANEPPS, its molar percentage
was kept below 0.33%.
2.3. Atomic force microscopy measurements
Imaging was performed using uncoated silicon nitride cantilevers
OMCL-TR800PSA-2 (Olympus, Tokyo, Japan), with a typical stiffness of
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contact mode. All images, for the different peptides, concentrations and
lipid compositions evaluated, were obtained with the same or close
AFM parameter (setpoint, scan rate, gain) values. The scan rate was set
to less than 1 Hz for intermittent contact mode and between 1.5 and
4 Hz for contact mode. The force applied on the sample was maintained
at the lowest possible value by continuously adjusting the setpoint and
gain during the imaging. Typically, setpoints close to 0.7 V for intermit-
tent contact and 0.3 V for contact modes were used. For intermittent
contact mode the cantilever oscillation was tuned to a frequency of
15–20 kHz. Height, error, deﬂection and phase-shift signalswere collect-
ed and images were line-ﬁtted as required. Tip artifacts were ruled out
by image analysis [23]. Images were obtained at least for 3–5 regions of
the lipid bilayers. Control experiments with buffer instead of enfuvirtide
or T-1249 were also performed.
Roughness analysis for some of the AFM height images (but also for
AFM error images and epiﬂuorescence images) was performed using
the approach described by Alves et al. [24]. The roughness was calculat-
ed from the rootmean square value (RMS; i.e. standard deviation, of the
distribution of heights, or other parameter). RMS valuesweremeasured
over the entire images and RMSmaps were obtained. RMS values on ld,
lo and so domains were compared within each map.
Force measurements were performed on POPC bilayers using
uncoated silicon cantilevers CSC38 from MikroMasch (Tallinn, Estonia),
with a spring constant of 0.12 N/m, as previously described [21]. Brieﬂy,
the calibration of the sensitivity, resonance frequency and effective
spring constant (via thermal noise method) of the cantilever was
performed before and after each experiment. The total z-piezo displace-
ment was always 200 nm; the indenting approach speed was set at
800 nm/s, while the retraction speed was 200 nm/s. Force measure-
mentswere carried out at different points of the lipid bilayers. After iden-
tiﬁcation of the membrane breakthrough events on an average of 225
approach force curves, the retrieved yield forces, for each experiment,
were plotted in histograms [25].
Statistical analysis of the AFM data was performed using one-way
analysis of variance (ANOVA) followed by Bonferroni multiple com-
parison test (interval of conﬁdence 95%).
2.4. Epiﬂuorescence imaging
Epiﬂuorescence imaging was conducted on the Zeiss microscope
where the AFM instrument is mounted. Fluorescence illumination was
achieved using an EXFO X-Cite 120 light unit (Mississauga, Canada)
with a high pressure 120 W metal halide short arc lamp, utilizing a
Zeiss ﬁlter set 09 (excitation BP 450–490; beamsplitter FT 510; emission
LP 515) and using a Zeiss 100× NA 1.3 UV–VIS-IR EC Plan-Neoﬂuar
oil-immersion objective. For detection, a Hamamatsu Photonics
C9100-13 Electron Multiplier CCD camera (Hamamatsu City, Japan)
was further used. Fluorescence images were acquired with a
512 × 512 pixel resolution, under normal CCD mode, using exposure
times below 1 s. Images were obtained at least for 3–5 regions of the
lipid bilayers. Control experiments with buffer instead of enfuvirtide or
T-1249 were also performed.
3. Results and discussion
3.1. Effect of the concentration of fusion inhibitors on lipid bilayer
organization
Intermittent-contact mode AFM was used to evaluate the effects of
enfuvirtide and T-1249 after 1 h incubation at different concentrations
(0, 1.5 μM and 15 μM) on POPC:DPPC, 1:1 molar (liquid disordered-gel,
ld–so, phase separation; Fig. 2) [18] and DOPC:DSPC:Chol, 2:2:1 molar
(liquid disordered-liquid ordered, ld–lo, phase separation; Fig. S2, Appen-
dix A) [26] lipid bilayers. These mixtures were used since they form sta-
ble and deﬁned ld–so and ld–lo phase separated domains [27,28]. Nomajor architectural modiﬁcations occurred on POPC:DPPC and DOPC:
DSPC:Chol bilayers when enfuvirtide was added at a 1.5 μM concentra-
tion. On the other hand, at 15 μM enfuvirtide, small membrane disrup-
tions (≈1 nm) on the ld matrix present at approximately 20% of the
scanned areas were detected at the borders of the POPC:DPPC ld–so
phase separations (Fig. 2A). On DOPC:DSPC:Chol bilayers, larger aggre-
gates appeared on the surface of the membranes (Fig. S2A). These can
be assigned to peptide–lipid complexes adsorbed on the surface of the
rigid cholesterol-enriched lo domains. The complexes may be formed
due to membrane solubilization or due to the disruption by the peptide
of unbound vesicles [26].
T-1249 at a 1.5 μM concentration did not promote signiﬁcant per-
turbations on the membrane, except for small aggregates that
appeared on the surface of the cholesterol-enriched lo domains on
DOPC:DSPC:Chol bilayers (Fig. S2B, Appendix A). However, at the
higher concentration, a major interaction was detected. On POPC:
DPPC bilayers, an increase of the roughness of the ld POPC matrix
and a slight perturbation of the so phase borders were detected
(Fig. 2B). These results show a preferential interaction and insertion
of the peptide on those membrane regions. On the other hand, large
aggregates were present on the surface of DOPC:DSPC:Chol bilayers
but no perturbation of the lo borders was observed. The large aggre-
gates, mainly on the DOPC ﬂuid matrix, may correspond to lipid and
peptide aggregates/vesicles that are being removed from the lipid bi-
layer, similar to the effect of detergent-like molecules [29].
Due to the presence of peptide aggregates on DOPC:DSPC:Chol bilay-
ers (Fig. S2, Appendix A), it was not possible to perform an accurate
roughness analysis on these systems. Roughness mapping, using the
root-mean square (RMS) calculation [24],was only performed for the ac-
quired POPC:DPPC AFM images. At 1.5 μMpeptide concentration no sig-
niﬁcant differences in the RMS values between ld and so domains were
detected for enfuvirtide and T-1249. In contrast, at a 15 μMpeptide con-
centration, an increase of the RMS of the ﬂuid ld matrix was clearly
shown (Fig. 2). To analyze the RMS images in more detail, we calculated
the ratio of the RMS values between ld and so domains. For enfuvirtide,
there is a slight increase in the RMS ratios from 1.00 ± 0.07 (without
peptide) to 1.17 ± 0.11 (at 1.5 μM peptide) and 1.23 ± 0.08 (at 15 μM
peptide). For 1.5 μM T-1249 a slight increase, from 1.00 ± 0.09 to
1.19 ± 0.09, is also detected. However, at 15 μM T-1249 the RMS ratio
is 2.76 ± 0.21, showing that the presence of this peptide in the POPC:
DPPC bilayer caused approximately a 3-fold increase in the roughness
of the ld membrane relative to so. An increase in membrane roughness
(and membrane morphological changes) has been already reported for
other HIV-related molecules such as HIV gp41 protein in the
post-fusion state [30] and NHR-derived peptides [31].
3.2. Effect of the fusion inhibitors' incubation time on the lipid bilayer
structure
A kinetic AFM study, under intermittent contact mode, was also
performed with POPC:DPPC bilayers.
Fig. 3 shows the effects of the incubation with 15 μM T-1249 at dis-
tinct time points (2 and 12 h). An increase in the roughness on the
ﬂuid POPC region was clearly observed both in height and error images.
Furthermore, the borders of the so domains are slightly perturbed and a
thinning of the membrane after the addition of peptide is also detected.
As the cross-sections depicted in Fig. 3B show, after the addition of
T-1249, the so-ld height difference is more pronounced, increasing from
1.0–1.2 nm prior the addition to 1.5–1.8 nm after the addition of
15 μM peptide. The extent of the thinning is in agreement with the
in-depth location of T-1249 in POPCmembranes, determined using ﬂuo-
rescence spectroscopy (Trp residues of the peptide at a 16–17 Å distance
from the bilayer center) [32], andmay be related to the interfacial inser-
tion of the peptide between the lipid headgroups. A similar membrane
effect, already visualized by AFM, has been described for an amphipathic
α-helical peptide derived from a hepatitis C viral protein [33]. Overall,
1.00 ± 0.07RMS (ld /so) 
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Fig. 2. AFM height images and root-mean square (RMS) maps (roughness analyses) of POPC:DPPC (1:1) bilayers after 1 h incubation with HEPES buffer (control), 1.5 μM and 15 μM
enfuvirtide (A) or T-1249 (B). The ratio between the RMS values obtained on the ld POPC matrix and so DPPC domains is presented below the roughness images. Values correspond
to the mean ± standard deviation of three to ﬁve measurements on separated regions of the bilayer. * P b 0.05, ** P b 0.01, *** P b 0.001 vs. the addition of peptide, one-way
ANOVA, Bonferroni test.
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branes (Fig. 3) are stable at least for 12 h, the last time-point evaluated.
Fig. S3 (Appendix A) shows a POPC:DPPC lipid bilayer region imaged
over 2 h in the presence of peptide. No major structural changes oc-
curred on the membrane upon addition of enfuvirtide, only a slight
membrane thinning of the membrane was detected. When T-1249 is
added, a pronounced thinning of the POPC ld bilayermatrix is observed,
togetherwith an enhanced perturbation of the so phase borders. The ex-
tent of so border destruction shown in Fig. S3 can be partially due to the
continuous scanning process, since in Fig. 3 those perturbations were
less evident. Similar perturbations have been already reported for the
membrane mode of action of a cell-penetrating peptide [34].3.3. Evaluation of the interaction of fusion inhibitors using combined
contact mode AFM and epiﬂuorescence
We further performed a combined AFM contact mode and
epiﬂuorescence acquisitions. Membranes were labeled with di-8-
ANEPPS, a probe only signiﬁcantly ﬂuorescent in lipidic environments
[35,36]. Our observations showed a preferential partition of this probe
into the ﬂuid ld domains. First, epiﬂuorescence images of the lipid bilay-
ers (size 83 × 83 μm2) were acquired. Then a second image was ac-
quired after 45 min incubation of the peptides (at 15 μM) with the
lipid bilayers. After 60 min incubation, AFM images were taken on spe-
ciﬁc regions previously detected on the epiﬂuorescence image.
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1781H.G. Franquelim et al. / Biochimica et Biophysica Acta 1828 (2013) 1777–1785The membrane domains observed on the epiﬂuorescence images
(Fig. S4A, Appendix A) of DOPC:DSPC:Chol membranes were very
small in size, with an approximate diameter of 0.5–3 μm. On the other
hand, the domains observed on POPC:DPPC lipid bilayers were much
larger (Fig. 4A), allowing for a more accurate evaluation of RMS images
(Fig. 4B). The RMS calculation of epiﬂuorescence images enabled us to
evaluate heterogeneities in the probe's lateral distribution that might
have occurred at the lipid bilayer level upon the addition of peptide.
For instance, the ﬂuorescence on the POPC matrix became less homog-
enous with the addition of 15 μM T-1249. By performing the RMS anal-
ysis of those ﬂuorescence images (Fig. 4B) an approximate 3-fold
increase in the RMS of the POPC ld matrix is detected for T-1249, but
not for enfuvirtide.
Images obtained by contact mode AFM (Fig. 4C) also demonstrat-
ed the same pattern, as previously described for intermittent-contact
mode and epiﬂuorescence images. While the RMS upon addition of
buffer or enfuvirtide is similar all over the lipid domains, the addition
of T-1249 promotes an approximate 3-fold increase in the RMS of the
POPC matrix. More detailed AFM images revealed that the increase in
roughness is due to the insertion of peptide and fragmentation of the
so phase borders; thus, smaller islets of so phase DPPC domains are
present in the ld POPC matrix.
In the case of DOPC:DSPC:Chol bilayers, upon the addition of buffer or
enfuvirtide, AFM images (Fig. S4B, Appendix A) demonstrated no signif-
icant perturbations of the lipid bilayer, except some sparse holes with a
typical depth of ≈3.5 nm. However, when T-1249 was added, more
holes become present all over the lipid bilayer. This effect, detected on
DOPC ﬂuid regions but non-signiﬁcant for membranes containing POPC
or more rigid lipids, can be explained by a detergent-like behavior of
the peptide, removing lipid primarily from the more ﬂuid DOPC regions.
Furthermore, these holes have a typical depth of≈2 nm, which can be
explained by the thinning of the bilayer or by the removal of the uppermonolayer by the peptide. The formation of such holes in planar bilayers
has been already detected by AFM for several peptides, such as antimi-
crobial peptides [37], amyloidogenic peptides [38] and, most signiﬁcant-
ly, theHIV-1 fusion peptide [31]. For the RMS analysis of the DOPC:DSPC:
Chol AFM images (Fig. S4C), only with T-1249 an increase is detected.
The regions with higher roughness correspond to those previously de-
scribed as having holes. Unlike intermittent contact mode AFM (Fig.
S2), no major aggregates are seen in contact mode, which may be due
to the facilitated dragging of adsorbedmaterial caused by the continuous
contact between the AFM tip and the sample.
3.4. Assessment of the interaction of fusion inhibitors using force
measurements
While all the imaging experiments showed an enhanced effect of
T-1249 on lipid bilayers, especially for POPC ﬂuidmembranes, we decid-
ed to evaluate if the peptide would also promote changes on the me-
chanical properties of the membrane. Besides imaging, AFM can be
used to measure forces. In this mode, the cantilever deﬂection is
recorded as a function of the z-piezo displacement, which relates to the
force applied by the AFM tip on the sample versus the tip-sample dis-
tance [25].Whilemeasuring force curves on supportedmembranes, typ-
ically a discontinuity or jump is observed when the tip compresses the
sample [25], as shown in Fig. 5A. This event corresponds to a certain
yield force, which is interpreted as the penetration of the AFM tip
through the bilayer. In other words, this event corresponds to the force
needed for the tip to break through the supported lipid bilayer (or simply
the breakthrough force in short), which is directly linked to themechan-
ical properties of the bilayer.
In this section, instead of using phase-separated bilayers, we used
pure POPC homogeneous membranes in order to reduce the complexity
of the system for a quantitative force analysis [21]. Here, we recorded
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yield force, i.e., the force required for the AFM tip to break through the supported lipid bilayer. (B) Histograms of the breakthrough forces on POPC planar bilayers prior and after the
addition of 15 μM enfuvirtide or T-1249. The force values displayed correspond to the mean yield force ± standard deviation of an average 225 force curves. *** P b 0.001 vs. the
addition of peptide, one-way ANOVA, Bonferroni test.
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cubation with 15 μM enfuvirtide or T-1249. We evaluated the break-
through events and recorded the forces needed for the tip to perforate
the lipid bilayer. The values were then compiled on the histograms
shown in Fig. 5B. POPC membranes displayed an average breakthrough
force of 2.4 nN. The addition of enfuvirtide caused no signiﬁcant changes
on this value. However, when 15 μM T-1249 was added, an approximate
3-fold reduction in the force needed for the tip to break the lipid bilayer
was detected. This indicates that the peptide is ﬂuidifying the mem-
branes, in accordance with the previously described insertion of the pep-
tide, increase inmembrane roughness andmembrane thinning. A similar
behaviorwas reported byGarcia-Saez et al. for a Bax-derivedpeptide [21].3.5. Intrinsic membranotropic effects of the hydrophobic functional
domains
The previously presented results show an enhancement of the
membranotropism of T-1249 in comparison to enfuvirtide at a global
concentration of 15 μM. This is in agreement with previous results
[32,39], in which we demonstrated, using ﬂuorescence spectroscopy,
that T-1249 presents a 3-fold higher partition coefﬁcient (Kp) for POPC
membranes, when compared to enfuvirtide (5.1 × 103 vs. 1.6 × 103, re-
spectively). Despite someminor differences in net charge and hydropho-
bicity on the residues that enfuvirtide and T-1249 share, the major
differences in membrane afﬁnity between the two peptides can be
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the intrinsic effect of the synergism between PBD and TRD, we evaluated
the effect of enfuvirtide and T-1249 at comparable membrane-bound
concentrations.
From the previously indicatedKp values, one can calculate the fraction
of membrane-bound (xL) enfuvirtide and T-1249, as described in [40].
Considering the diameter of the mica substrate used to deposit the sup-
ported bilayer, the experimental volume and the surface area of the phos-
pholipids used, one can estimate the amount of lipid involved in the
formation of supported membranes and subsequently determine the
fraction of membrane-bound enfuvirtide and T-1249: for enfuvirtide,
4.1%; for T-1249, 13%. Thus, in order to have comparable amounts of
membrane-bound enfuvirtide andT-1249, a global experimental concen-
tration of 15 μM T-1249 (~200 nMwithin the membrane volume) and a
global concentration of 47.5 μMenfuvirtide canbe tested byAFM.As seen
in Fig. S5 (Appendix A), even at a comparablemembrane-bound concen-
trations, enfuvirtide and T-1249 display distinct membrane-interaction
patterns on POPC:DPPC (1:1) membranes. In the presence of 47.5 μM
enfuvirtide, aggregation was observed on top of POPC:DPPC bilayers. In
opposition, for 15 μM T-1249, insertion of the peptide on ld domains
and an increase in membrane roughness are detected. This distinct be-
havior demonstrates a cooperative role of the PBD and TRD for the en-
hancement of the membrane activity of FIs.
In addition, peptides presenting only the PBD region have been
reported to have low to non-signiﬁcant afﬁnity towards lipids. Liu et al.
[13] demonstrated, for instance, that the FI peptide C36 does not interact
signiﬁcantly with POPC vesicles. Sifuvirtide, a recent FI derived from the
CHR region of gp41, presents a selective, albeit ratherweak adsorption to
DPPC gel phase vesicles [17,18]. Fig. S6 (Appendix A) shows that, for a
global concentration of 15 μM sifuvirtide, no signiﬁcant effects on the
POPC:DPPC (1:1) supported lipid bilayer architecture are revealed
using AFM imaging. These results are in agreement with a major role
displayed by the TRD on the interactions of enfuvirtide or T-1249 with
membranes, reinforcing the conclusion of a mechanism of functional co-
operation between the PBD and TRD for the interaction of T-1249 with
lipid membranes.
4. Conclusions
HIV gp41 CHR-derived FI peptides are molecules that contain
multifunctional domains [41]. Distinct mechanisms of action may pro-
vide more alternatives to tackle HIV-1 inhibition. The modulation of
the structure of CHR-derived FIs and the inclusion of the PBD and TRD,
individually or simultaneously, give rise to FIs with distinct capabilities.
Considering the emergence of drug-resistant HIV-1 variants, having
in the near future efﬁcient alternatives to the FDA-approved drug
enfuvirtide is one of the primary goals in the ﬁeld of HIV treatment. For
that reason, understanding the details underlying themechanisms of ac-
tion of FIs, including interactions with lipid membranes, is fundamental.
In this work, we studied the mode of action at the lipid membrane
level of two FIs: enfuvirtide and T-1249. As seen in Fig. 1, both peptides
possess the gp41 TRD at the C-terminal, but only T-1249 has the
N-terminal PBD [41]. While the TRD may enhance the hydrophobicity
of the peptide, the PBD on the other hand enhances the peptide's amphi-
pathic characteristics (Fig. S1, Appendix A). We followed the interaction
of both peptides with lipid membranes by AFM and epiﬂuorescencemi-
croscopy. The results demonstrated that T-1249 has an increased afﬁnity
for lipid membranes, mainly for ﬂuid ld POPC membranes, with an in-
crease in membrane roughness due to peptide insertion, membrane
thinning and ﬂuidiﬁcation. While it was also proven that enfuvirtide
has afﬁnity for lipids, the extent and complexity of this interaction are
lower when compared to T-1249. Moreover the differences between
enfuvirtide and T-1249 in terms of membrane interaction cannot solely
be attributed to the fraction of membrane-bound peptide, neither to
the action of the PBD region by itself (as seen from the interaction of
sifuvirtide with supported lipid bilayers [18]). Hence, the majordifferences observed here can be correlated to the presence of tandem
PBD-TRD functionality in T-1249, enhancing its lipid interaction proﬁle.
Distinct roles for the TRD and PBD regions of FI peptides have been
proposed by several groups (see references [1,2] for more details). Liu
et al. [13] proposed that peptides presenting the PBD inhibit HIV-1 fusion
by interacting with gp41 NHR, forming stable 6HB and blocking gp41
core formation; while peptides lacking the PBD and possessing the
C-terminal TRD (such as enfuvirtide)would block viral fusion by binding
to gp41 NHR and by binding its C-terminal sequence to cell membranes.
While the role of the TRD as promoter of the interaction of FIswithmem-
branes has becomewidely accepted, seminal results in the literaturemay
have already pointed out this putative role of the PBD in themodulation
of interaction of FIs with lipids. Yet the topic was still poorly addressed
until now. For instance, Wexler-Cohen et al. already demonstrated that
peptides similar to enfuvirtide, but truncated at the C-terminal in order
to lack the TRD, partially or fully regain antiviral activity upon the addi-
tion of a lipophilic moiety at the C-terminal (native position of the TRD
region), N-terminal (native position of the PBD region) or both [42]. Qi
et al. also demonstrated that peptides possessing artiﬁcial HR and
containing both TRD and PBD presented higher antiviral potency and
increased lipid membrane afﬁnity, when compared to peptides formed
by artiﬁcial HR containing only either the C-terminal TRD or the
N-terminal PBD [43]. Recently, small molecules that bind the hydropho-
bic deep pocket on the gp41 NHR core (the region to which the PBD re-
gion binds) have been reported to present afﬁnity for fatty acid salts [44]
and lipid membranes [45,46]. Finally, our previous results with
enfuvirtide [39,47], T-1249 [32,47] and sifuvirtide [17,18,48] using lipid
membranemodels, erythrocytes and PBMC enabled us to hint that coop-
eration between the hydrophobic domains at both ends of CHR-derived
fusion inhibitors could dictate efﬁcacy based on the membrane interac-
tion of those antiviral molecules.
In summary, the results in this work provide insights concerning the
mode of action and the role of both PBD and TRD regions in the modu-
lation of the lipid membrane interaction proﬁles of FI peptides. T-1249,
which contains both functional domains, has an enhanced afﬁnity for
lipid membranes. This enhanced tropism can be explained by the coop-
eration and synergism of both hydrophobic C-terminal end and amphi-
pathic N-terminal end of the peptide, which ultimately improves
several folds the interaction with lipid membranes. Potentiating mem-
brane interactions, aside from the direct binding to gp41, is a crucial fac-
tor to be taken into consideration during the design and development of
more efﬁcient antiretrovirals against HIV. This work also demonstrates
that biophysical techniques such as tandem AFM and ﬂuorescence
methodologies, with tailored data analyses, are capable of providing
clear and detailed information concerning the mode of action of
membrane-active molecules.
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